Showing results (1-10 of 329) with videos related to

Sort By:
Pageof 33
Journal of Clinical Medicine|July 9, 2022
Substance P-Friend or FoePrema Robinson, Emma Rodriguez, Miguel Muñoz
Journal of Clinical Medicine|March 29, 2023
Neurokinin-1 Receptor Antagonists as a Potential Novel Therapeutic Option for Osteosarcoma PatientsPrema Robinson, Marisa Rosso, Miguel Muñoz
Current Medicinal Chemistry|August 12, 2022
Combination Therapy of Chemotherapy or Radiotherapy and the Neurokinin-1 Receptor Antagonist Aprepitant: A New Antitumor Strategy?Prema Robinson, Rafael Coveñas, Miguel Muñoz
International Journal of Molecular Sciences|November 14, 2023
The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for AprepitantRafael Coveñas, Francisco D Rodríguez, Prema Robinson, et al.
Cancers|August 7, 2021
Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and ApoptosisEmma Rodriguez, Guangsheng Pei, Sang T Kim, et al.
Cancers|April 30, 2021
Substance P Antagonism Prevents Chemotherapy-Induced CardiotoxicityAshiq Legi, Emma Rodriguez, Thomas K Eckols, et al.
NPJ Precision Oncology|July 14, 2026
Neurokinin-1 receptor antagonism as a potential therapeutic strategy for cancer treatment; enhancing anti-tumor efficacy while mitigating treatment-related toxicitiesAnirban Maitra, Miguel Muñoz, Rafael Coveñas, et al.
Cancers|November 27, 2025
The Involvement of the Peptidergic Systems in Breast Cancer DevelopmentManuel L Sánchez, Prema Robinson, Zal Italia, et al.
Cancers|October 23, 2021
Erratum: Rodriguez et al. Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. <i>Cancers</i> 2021, <i>13</i>, 3871Emma Rodriguez, Guangsheng Pei, Zhongming Zhao, et al.
International Journal of Molecular Sciences|October 16, 2025
A Dual-Purpose Approach for an Anti-Emetic NK1R Antagonist as a Chemosensitizer and Cardioprotectant in a Preclinical Model of Triple-Negative Breast CancerMiguel Muñoz, Rafael Coveñas, Younus Zuberi, et al.
Pageof 33